Although considerable progress has been made in identifying supportive care issues in HCT survivors, large, prospective trials demonstrating the effectiveness of supportive care interventions for HCT-related complications are needed to guide future development of evidence-based guidelines. Importantly, because long-term HCT recipients may no longer be followed by transplant centers, recommendations for supportive care should be geared toward community healthcare providers who may not routinely care for HCT recipients.

Management of pediatric patients with cancer is complex and requires multidisciplinary coordination to organize cancer treatment and supportive care during treatment. In addition, care coordination is essential during the survivorship and end-of-life phases of pediatric cancer treatment.

The new combination immunotherapy + chemotherapy regimens represent a major change in systemic therapy for patients with metastatic NSCLC. Case managers and other health care providers have less experience with these new immunotherapy + chemotherapy regimens or the newer targeted therapies that have different mechanisms of action and side effects than traditional cytotoxic chemotherapy regimens.

To ensure safe access to opioid pain medications for patients with cancer, all members of the healthcare team need to understand the benefits of opioids, how to navigate the federal and state programs regulating opioid use, and how to develop strategies to prevent opioid misuse.

Case managers and medical directors are challenged to maintain a high awareness of the recent therapeutic advances in the management of FL and DLBCL in order to develop an efficient coordinated treatment approach that incorporates novel therapies in the appropriate patient population.

It is important for clinicians to be aware of the updated criteria to appropriately select patients who are sensitive to HER2-targeted agents; to stay up-to-date with evolving treatment strategies; to understand how to choose optimal treatment based on patient preference, toxicities, and drug availability; and to effectively evaluate patients during therapies and manage any therapy-related adverse effects.